Treatment of Thyrotoxicosis

Introduction to Thyrotoxicosis Management

The American College of Clinical Oncology recommends treating thyrotoxicosis with conservative management using beta-blockers for symptomatic relief, with close monitoring for the expected transition to hypothyroidism that will require levothyroxine replacement therapy 1, 2

Beta-blocker therapy (atenolol or propranolol) is used for symptomatic control of palpitations, tremors, and anxiety in patients with mild symptoms (Grade 1) 1, 2
The American College of Clinical Oncology suggests continuing monitoring thyroid function every 2-3 weeks to detect transition to hypothyroidism in patients with mild symptoms (Grade 1) 1, 2
For moderate symptoms (Grade 2), consider holding causative medications if drug-induced, and use beta-blocker therapy plus hydration and supportive care 2
The American Society of Clinical Oncology recommends endocrinology consultation if thyrotoxicosis persists beyond 6 weeks in patients with moderate symptoms (Grade 2) 1, 2

Hospitalization with endocrine consultation is required for all patients with severe symptoms (Grade 3-4) 2, 5
Beta-blocker therapy is used in patients with severe symptoms (Grade 3-4) 2, 5
Additional medical therapies may include steroids, SSKI (saturated solution of potassium iodide), or thionamides (methimazole or propylthiouracil) in patients with severe symptoms (Grade 3-4) 2, 5

The American Thyroid Association recommends distinguishing thyroiditis from Graves' disease, as treatment differs substantially 2
Thyroiditis is self-limiting, requires only supportive care, and transitions to hypothyroidism within 1 month 3, 4, 6
Graves' disease is persistent hyperthyroidism requiring antithyroid medications, radioactive iodine, or surgery 2

TSH receptor antibody (TRAb) or thyroid stimulating immunoglobulin (TSI) testing is used to differentiate between thyroiditis and Graves' disease 3, 4
Thyroid peroxidase (TPO) antibody testing is used to differentiate between thyroiditis and Graves' disease 3, 4
Radioactive iodine uptake scan (RAIUS) or Technetium-99m scan is used to differentiate between thyroiditis and Graves' disease 3, 4

Thyroiditis-induced thyrotoxicosis typically progresses to permanent hypothyroidism within 1 month after the thyrotoxic phase 3, 4, 6
Levothyroxine replacement therapy is initiated when TSH becomes elevated and free T4 drops 1, 2, 7
The American Association of Clinical Endocrinologists recommends dosing for patients without cardiac disease or frailty at approximately 1.6 mcg/kg/day based on ideal body weight 1, 2, 7

Never start thyroid hormone replacement during active thyrotoxicosis, even if planning for eventual hypothyroidism 1, 2
If concurrent adrenal insufficiency exists, always start corticosteroids before thyroid hormone to prevent adrenal crisis 4, 6
Do not use antithyroid medications (methimazole, propylthiouracil) for thyroiditis-induced thyrotoxicosis, as this is self-limiting and does not involve true thyroid hormone overproduction 3, 4, 2

Mandatory endocrinology consultation is required for all cases of suspected or confirmed hyperthyroidism or thyroiditis 3, 4
Thyrotoxicosis persisting beyond 6 weeks requires endocrinology consultation 1, 2
Grade 3-4 severe symptoms require endocrinology consultation 2, 5
Difficulty distinguishing thyroiditis from Graves' disease requires endocrinology consultation 2
Presence of ophthalmopathy or thyroid bruit requires endocrinology consultation 2